Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

References

• Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, Reid RD. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians. 1976;89:184–94.
   PubMedGoogle Scholar
• Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977;238(24):2613–16. doi:10.1001/jama.1977.03280250039019.
   PubMed Web of Science ®Google Scholar
• Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine. 1998;16(14–15):1391–95. doi:10.1016/S0264-410X(98)00097-8.
   PubMed Web of Science ®Google Scholar
• Westerink MA, Schroeder HW Jr, Nahm MH. Immune Responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis. 2012;3:51–67.
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–18.
   PubMedGoogle Scholar
• Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 years. Expert Opin Biol Ther. 2018;18(1):7–17. doi:10.1080/14712598.2018.1384462.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Active bacterial core surveillance/emerging infections program network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648593.
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–24. doi:10.1093/cid/ciu006.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–43. doi:10.1016/S1473-3099(15)70044-7.
   PubMed Web of Science ®Google Scholar
• Prevnar 13 [package insert]. Philadelphia (PA, USA): Wyeth Pharmaceuticals Inc. Accessed 2020 Mar 23. https://www.fda.gov/media/107657/download
   Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Centers for disease control and prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–25.
   PubMed Web of Science ®Google Scholar
• Pneumovax 23 [package insert]. Kenilworth (NJ, USA): Merck & Co., Inc. Accessed 2020 Mar 23. https://www.fda.gov/media/80547/download
   Google Scholar
• Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26(43):5521–26. doi:10.1016/j.vaccine.2008.07.071.
   PubMed Web of Science ®Google Scholar
• Musher DM. How effective is vaccination in preventing pneumococcal disease? Infect Dis Clin North Am. 2013;27(1):229–41. doi:10.1016/j.idc.2012.11.011.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine. 2013;31(37):3950–56. doi:10.1016/j.vaccine.2013.06.037.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816–19.
   PubMedGoogle Scholar
• Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-Infected adult: a review of the current recommendations, part I. Infect Dis Ther. 2017;6(3):303–31. doi:10.1007/s40121-017-0166-x.
   PubMedGoogle Scholar
• Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-Infected adult: a review of the current recommendations, part II. Infect Dis Ther. 2017;6(3):333–61. doi:10.1007/s40121-017-0165-y.
   PubMedGoogle Scholar
• Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10–27. doi:10.1016/j.jaut.2017.03.011.
   PubMed Web of Science ®Google Scholar
• Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069–75. doi:10.15585/mmwr.mm6846a5.
   PubMed Web of Science ®Google Scholar
• Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, Flamaing J. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis. 2019;38(4):785–91. doi:10.1007/s10096-019-03485-3.
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55–70 years of age. Clin Infect Dis. 2009;49(2):241–48. doi:10.1086/599824.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis. 2009;49(9):1318–25. doi:10.1086/606046.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine. 2014;32(20):2364–74. doi:10.1016/j.vaccine.2014.02.002.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594–602. doi:10.1016/j.vaccine.2013.04.084.
   PubMed Web of Science ®Google Scholar
• Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother. 2014;10(5):1343–53. doi:10.4161/hv.27998.
   PubMed Web of Science ®Google Scholar
• Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004–09. doi:10.1128/CVI.00112-06.
   PubMedGoogle Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211.
   PubMed Web of Science ®Google Scholar
• Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Indian J Stat. 2000;62:134–48.
   Google Scholar
• Musher DM, Rodriguez-Barradas MB. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother. 2016;12(2):331–35. doi:10.1080/21645515.2015.1098794.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Shapiro ED. Prevention of pneumococcal infections in adults using conjugate vaccines: no easy answers. Clin Infect Dis. 2019 Jun 18;69(1):50–51. doi:10.1093/cid/ciy873.
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, Andrews NJ. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2019;6:42–50. doi:10.1016/j.eclinm.2018.12.007.
   PubMedGoogle Scholar
• Marra F, Vadlamudi NK. Efficacy and safety of the pneumococcal conjugate-13 valent vaccine in adults. Aging Dis. 2019;10(2):404–18. doi:10.14336/AD.2018.0512.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944–47. doi:10.15585/mmwr.mm6434a4.
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46(7):1015–23. doi:10.1086/529142.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198–206. doi:10.1080/21645515.2015.1030550.
   PubMed Web of Science ®Google Scholar
• Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018;36(45):6875–82. doi:10.1016/j.vaccine.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Hurley D, Griffin C, Young M Jr, Scott DA, Pride MW, Scully IL, Ginis J, Severs J, Jansen KU, Gruber WC, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2020; in press. doi:10.1093/cid/ciaa1045.
   Google Scholar
• Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: the role of risk stacking. Open Forum Infect Dis. 2015;2(1):ofy020. doi:10.1093/ofid/ofv020.
   Web of Science ®Google Scholar
• Morton JB, Morrill HJ, LaPlante KL, Caffrey AR. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections. Vaccine. 2017;35(13):1692–97. doi:10.1016/j.vaccine.2017.02.026.
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Pondo T, Xing W, McGee L, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lynfield R, et al. Early Impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States. Clin Infect Dis. 2020;70(12):2484–92. doi:10.1093/cid/ciz739.
   Web of Science ®Google Scholar
• McLaughlin JM, Swerdlow DL, Isturiz RE, Jodar L. Decision-making for PCV in adults. Hum Vaccin Immunother. 2019;15(3):584–93. doi:10.1080/21645515.2018.1538611.
   PubMed Web of Science ®Google Scholar
• Colijn C, Corander J, Croucher NJ. Designing ecologically optimized pneumococcal vaccines using population genomics. Nat Microbiol. 2020 Mar 5;3:473–85. doi:10.1038/s41564-019-0651-y.
   PubMed Web of Science ®Google Scholar
• Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, Makela PH, Broome CV, Facklam RR, Tiesjema RH, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within the groups. J Infect Dis. 1983;148(6):1136–59. doi:10.1093/infdis/148.6.1136.
   PubMed Web of Science ®Google Scholar